<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794204</url>
  </required_header>
  <id_info>
    <org_study_id>RMP-A03-001</org_study_id>
    <nct_id>NCT05794204</nct_id>
  </id_info>
  <brief_title>RMP-A03 Ocular Suspension in Patients With Pterygium</brief_title>
  <official_title>A Phase 2a Study Evaluating the Safety and Efficacy of RMP-A03 Ocular Suspension in Patients With Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Raymon Pharmaceuticals Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WuXi Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Suzhou Raymon Pharmaceuticals Company, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to test the safety and efficacy of an ocular medication on&#xD;
      the treatment of pterygium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following informed consent, patients with pterygium who meet all eligibility criteria will be&#xD;
      randomized to an 84-day double-blinded study to measure the safety and efficacy of the study&#xD;
      drug as compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized in a 1:1:1 fashion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor/CRO clinical operations team will also be masked. Sponsor/CRO biostats team and drug supply manager will be unmasked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pterygium hyperemia grading at Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Pterygium hyperemia grading will be assessed by the principal investigator based on predefined vascularity scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pterygium characteristics at Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Pterygium size will be measured by the principal investigator based on predefined scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>Patients randomized to dose 1 study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 patients randomized to dose 1 of RMP-A03</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients randomized to dose 2 of study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 patients randomized to dose 2 of RMP-A03</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients randomized to placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 25 patients randomized to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMP-A03 - Dose 1</intervention_name>
    <description>Patients will randomized to dose 1 of RMP-A03</description>
    <arm_group_label>Patients randomized to dose 1 study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMP-A03 - Dose 2</intervention_name>
    <description>Patients will be randomized to dose 2 of RMP-A03</description>
    <arm_group_label>Patients randomized to dose 2 of study drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RMP-A03 Placebo</intervention_name>
    <description>Patients will be randomized to RMP-A03 Placebo</description>
    <arm_group_label>Patients randomized to placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be at least 18 years old&#xD;
&#xD;
          -  Diagnosis of pterygium with specified characteristics&#xD;
&#xD;
          -  BCVA of 20/200 or better&#xD;
&#xD;
          -  Willingness to attend all study visits and comply with the study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of ocular disease&#xD;
&#xD;
          -  Double pterygium&#xD;
&#xD;
          -  History of ocular surgery&#xD;
&#xD;
          -  Presence of ocular trauma&#xD;
&#xD;
          -  Use of any ocular medication&#xD;
&#xD;
          -  Use of contact lens&#xD;
&#xD;
          -  Allergy to any of the components of study drug&#xD;
&#xD;
          -  Cannot properly administer study drug&#xD;
&#xD;
          -  Clinically significant systemic disease that may place the subject at risk or confound&#xD;
             study results&#xD;
&#xD;
          -  Participation in an investigational study within 30 days prior to screening&#xD;
&#xD;
          -  Female participants who are pregnant, nursing, planning a pregnancy, or not using a&#xD;
             medically acceptable form of birth control (WOCBP).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashlea Beck</last_name>
    <phone>512-284-0103</phone>
    <email>ashlea.beck@raymonpharma.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

